Search
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalIt is currently sold in Australia under the Valdoxan trade name. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.
Uridine triacetate
go.drugbank.com/drugs/DB09144ApprovedWhen administered as the prodrug uridine triacetate, uridine can be used by essentially all cells to make uridine nucleotides, which compensates for the genetic deficiency in synthesis in patients with … It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself.
Sulindac
go.drugbank.com/drugs/DB00605ApprovedInvestigationalin the bile and then reabsorbed from the intestines. … Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions.
Lacidipine
go.drugbank.com/drugs/DB09236ApprovedIt displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. … Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout [A31539
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidinePinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.
Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10293ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*
Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADETCX-052075
go.drugbank.com/drugs/DB31655Approved[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from